Evotec to supply Procter & Gamble with R&D services

Under the terms of the agreements, P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.

A relationship between Evotec and P&GP started at the end of 2004 with a pilot screening programme for a challenging P&GP therapeutic target.

Dr Joseph Gardner, director of chemistry and discovery technologies at Procter & Gamble Pharmaceuticals commented, “Adding flexible and highly competent R&D capacity is an important element in our corporate strategy. Evotec’s capabilities and track record in each of the research disciplines, their state-of-the-art proprietary technologies and the scale of their operations make us believe that Evotec is an ideal provider of services for us in pharmaceutical research”